1. Home
  2. BCDA vs AIRE Comparison

BCDA vs AIRE Comparison

Compare BCDA & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$1.11

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$1.53

Market Cap

11.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCDA
AIRE
Founded
N/A
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1M
11.5M
IPO Year
2009
2023

Fundamental Metrics

Financial Performance
Metric
BCDA
AIRE
Price
$1.11
$1.53
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$25.00
$1.30
AVG Volume (30 Days)
208.4K
89.6K
Earning Date
05-13-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.34
EPS
N/A
N/A
Revenue
$479,000.00
$4,518,498.00
Revenue This Year
N/A
$129.06
Revenue Next Year
N/A
$83.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
376.42
52 Week Low
$0.75
$0.16
52 Week High
$2.29
$3.98

Technical Indicators

Market Signals
Indicator
BCDA
AIRE
Relative Strength Index (RSI) 60.76 49.31
Support Level $1.11 $1.29
Resistance Level $1.28 $1.64
Average True Range (ATR) 0.07 0.15
MACD 0.01 0.01
Stochastic Oscillator 66.36 42.58

Price Performance

Historical Comparison
BCDA
AIRE

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

Share on Social Networks: